Navigation Links
China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
Date:2/26/2013

6,6667,3711,183Prepaid expenses and other receivables

11,56113,2722,130Trading securities

354--Debt issuance costs

-3,704595Deferred tax assets

5,2685,868942Total current assets897,1721,588,951255,044Property, plant and equipment, net

267,862382,21661,350Non-current prepayments

2,863226,90436,420Non-current accounts receivable, less allowance for doubtful accounts(March 31, 2012: RMB38,628; December 31, 2012: RMB39,384)

254,236248,66339,913Inventories

34,65138,7836,225Intangible assets, net

129,791126,32620,277Available-for-sale equity securities

98,19977,06012,369Other investment

134,363134,36321,567Debt issuance costs

-12,6632,033Deferred tax assets

5,0135,082816Total assets1,824,1502,841,011456,014LIABILITIESCurrent liabilitiesBank loan

45,00050,0008,026Accounts payable

6,34316,9142,715Accrued expenses and other payables

33,35179,29212,728Deferred revenue

106,110147,60823,693Amounts due to related party

360720116Income tax payable

5,9438,3611,342Total current liabilities197,107302,89548,620Convertible notes

-748,075120,074Non-current deferred revenue

306,534474,60576,179Other non-current liabilities

60,42088,83614,259Deferred tax liabilities

24,46223,1913,722Total liabilities588,5231,637,602262,854EQUITYShareholders' equityOrdinary shares-
US$0.0001 par value, 250,000,000 shares authorized, 73,140,147shares issued and outstanding as of March 31, 2012 and 73,140,147 shares issued and 73,003,248 shares outstandingas of December 31, 2012

50508Additional paid-in capital

865,654798,221128,123Treasury stock, at cost
(March 31, 2012: nil; December 31, 2012: 136,899 shares)

-(2,815)(452)Accumulated other comprehensive income

26,0573,297529Retained earnings

310,973400,39264,268Total shareholders' equity1,202,73
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
2. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
3. Infectious Immunology Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
4. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
5. China Cord Blood Corporation to Further Consolidate its Corporate Structure
6. Biomaterials China News 1210 - Annual Subscription
7. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
10. China Biologic Products to Report Third Quarter 2012 Financial Results
11. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... has granted marketing authorization for EFFENTORA(TM), a buccal,tablet ... treatment of,breakthrough cancer pain (BTCP) in adult patients ... pain. The approval allows Cephalon,to market EFFENTORA in ...
... blood-based ColonSentry(TM) test -, TORONTO, April 14 ... on developing blood-based biomarker tests for the early,detection ... performance results from a large validation study of ... patient,s current risk for,colorectal cancer. This panel forms ...
... ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced ... 11, 2008 indicating that for the last 30,consecutive business ... closed,below $1.00 per share. As a result, the company ... continued listing set forth in,Marketplace Rule 4310(c)(4)., In ...
Cached Biology Technology:Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 9, 2009 A nutritionist whose research was instrumental in ... Children (WIC) food subsidy will receive the March of Dimes ... maternal-fetal nutrition. Gail Harrison, Ph.D., MNS, , ... the University of California, Los Angeles School of Public Health, ...
... 150th anniversary this month of the publication of On ... Sciences (AIBS) is publishing open access two peer-reviewed articles ... , The two articles are by Kevin Padian of ... of Western Carolina University. Padian,s article, "Ten Myths About ...
... Conn.Researchers at Yale University have developed synthetic molecules capable ... HIV-infected cells, as well as to prostate cancer cells. ... the American Chemical Society , could lead to novel ... called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting ...
Cached Biology News:March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2New synthetic molecules trigger immune response to HIV and prostate cancer 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
Biology Products: